Neumora Q2 net loss narrows to $43.1m
- Neumora Therapeutics reported a Q2 2026 net loss of $43.1 million, improving from $52.7 million a year earlier.
- NMRA’s latest available premarket quote was up about 1.2% at $1.73 following the results.
- Neumora says its $116.8 million cash balance should fund operations into Q3 2027 as three pipeline programs approach clinical milestones.
Neumora Therapeutics (NASDAQ:NMRA) reported a Q2 2026 net loss of $43.1 million, narrowing from $52.7 million a year earlier.
R&D expense declined to $29.3 million from $38.7 million, while G&A spending fell to $12.9 million from $15.3 million.
Neumora held $116.8 million in cash at June 30 and expects that balance to support its current operating plan into Q3 2027.
Following the announcement, Neumora Therapeutics' share price was up about 1.2% at $1.73 in the latest available premarket quote.
Neumora appointed Joshua Pinto as president and CEO, moved co-founder Paul Berns to Executive Chair and named Doron Sagman chief medical officer.
The company expects NMRA-215 to enter Phase 1 by year-end, NMRA-511 Phase 2 to begin by year-end and NMRA-898 Phase 1 data in the second half.
Frequently asked questions
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
